Merck’s Keytruda-Lenvima Combination Shows Promise in Liver Cancer Treatment
Keytruda, Lenvima, liver cancer, hepatocellular carcinoma, combination therapy, Merck, Eisai, clinical trials.
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy
Novo Nordisk and Korro Bio Collaborate on $530M RNA Editing Deal for Cardiometabolic Diseases
Novo Nordisk, Korro Bio, RNA editing, cardiometabolic diseases, genetic medicines, pharmaceutical partnerships
ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer
AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24
Exact Sciences Advances Toward FDA Submission with Promising Blood-Based Colorectal Cancer Screening Test
Exact Sciences, Blood-Based Colorectal Cancer Screening, ESMO 2024, FDA Submission, Colorectal Cancer Detection, Advanced Precancerous Lesions
FDA Advisory Committee Votes Against Ocaliva for Primary Biliary Cholangitis Due to Safety Concerns
Ocaliva, FDA, Primary Biliary Cholangitis, Liver Disease, Safety Concerns, Advisory Committee Vote
Streamlining Drug Development: The Power of Phase-Appropriate Technology Transfers
Technology Transfer, Phase-Appropriate Technology Transfer, Drug Development, Pharmaceutical Manufacturing, CDMOs (Contract Development and Manufacturing Organizations), Regulatory Compliance, Innovation in Drug Development
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
FDA Approves Ebglyss (Lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis in Adults and Children 12 Years and Older
Ebglyss, Lebrikizumab-lbkz, FDA Approval, Moderate-to-Severe Atopic Dermatitis, Eczema Treatment
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer
AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial